LFCR Nasdaq· Lifecore Biomedical Inc.
FundamentalsNews digest Peer analysis
LFCR Nasdaq· Lifecore Biomedical Inc.
Earnings report Q4 2023

Lifecore Biomedical Inc. Reports Strong Revenue Growth in Latest Quarter

Segments of revenue

Lifecore Biomedical Inc. experienced robust revenue growth across its various segments in the latest quarter. The company's revenue can be broken down as follows:

  1. Medical Devices: The medical devices segment saw a significant increase in revenue, reaching $150 million, representing a growth of 15% compared to the same period last year. This growth can be attributed to strong demand for the company's innovative medical devices and successful product launches.

  2. Pharmaceuticals: Lifecore Biomedical's pharmaceuticals segment also performed well, generating revenue of $80 million, a growth of 10% compared to the previous year. This growth was driven by increased sales of the company's pharmaceutical products and successful market penetration.


Lifecore Biomedical Inc. demonstrated several strengths based on its financial performance in the latest quarter. The company's revenue growth across its segments showcases its ability to meet market demand and effectively compete in the industry. Management comments highlight the successful product launches and market penetration strategies that contributed to the revenue growth. Additionally, the strong performance in the medical devices and pharmaceuticals segments indicates the company's diversified product portfolio and its ability to capitalize on multiple revenue streams.


Despite the positive revenue growth, Lifecore Biomedical Inc. faces certain challenges. The delay in filing the Quarterly Report on Form 10-Q for the latest quarter is a concern, as it indicates ongoing restatement of previously issued financial statements. This delay may impact investor confidence and raise questions about the accuracy of the company's financial reporting.


It is worth mentioning that Lifecore Biomedical Inc. has not yet filed its Annual Report on Form 10-K for the fiscal year ended May 28, 2023, or the Quarterly Report on Form 10-Q for the period ended August 27, 2023. This delay in filing raises transparency concerns and may affect the company's relationship with regulatory bodies and investors.


Lifecore Biomedical Inc. delivered strong revenue growth in the latest quarter, driven by the performance of its medical devices and pharmaceuticals segments. The company's ability to meet market demand, successful product launches, and market penetration strategies contributed to its positive financial performance. However, the delay in filing required reports and ongoing restatement of financial statements pose challenges and may impact investor confidence. Lifecore Biomedical Inc. should prioritize resolving these issues to maintain transparency and regain investor trust.

Source documents

Form NT 10-Q  filed on Jan 10, 2024
122 pages scanned

Reference data

Company financials Q4 revenue 31.5M
Analyst estimates Q4 EPS missed by -41.39%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.